Connor, Clark & Lunn Investment Management (CC&L)
FATE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Fate Therapeutics FATE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$564K Buy
469,785
+358,558
+322% +$437K ﹤0.01% 1291
2025
Q4 		$109K Buy
+111,227
New +$134K ﹤0.01% 1481
2023
Q1 		– Sell
-380,862
Closed -$3.84M – 1310
2022
Q4 		$3.84M Buy
380,862
+81,048
+27% +$1.52M 0.02% 405
2022
Q3 		$6.72M Buy
299,814
+245,639
+453% +$7.1M 0.04% 265
2022
Q2 		$1.34M Buy
54,175
+46,510
+607% +$1.28M 0.01% 557
2022
Q1 		$297K Buy
+7,665
New +$297K ﹤0.01% 876
2021
Q3 		– Sell
-71,184
Closed -$6.18M – 1104
2021
Q2 		$6.18M Buy
71,184
+6,999
+11% +$564K 0.03% 316
2021
Q1 		$5.29M Buy
64,185
+31,410
+96% +$3.01M 0.03% 343
2020
Q4 		$2.98M Buy
32,775
+25,571
+355% +$1.59M 0.02% 428
2020
Q3 		$288K Buy
+7,204
New +$252K ﹤0.01% 796
2018
Q1 		– Sell
-28,900
Closed -$177K – 742
2017
Q4 		$177K Sell
28,900
-36,100
-56% -$161K ﹤0.01% 729
2017
Q3 		$257K Buy
65,000
+1,500
+2% +$5.1K ﹤0.01% 725
2017
Q2 		$206K Buy
63,500
+22,200
+54% +$85.1K ﹤0.01% 740
2017
Q1 		$188K Buy
+41,300
New +$151K ﹤0.01% 806

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FATE Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Fate Therapeutics (FATE) stake by 322% in Q1 2026, buying an estimated $437K and bringing the position to 469,785 shares worth $564K. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FATE in Q1 2017 and has held it in 14 quarters since. The position peaked at $6.72M in Q3 2022. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 469,785 shares of Fate Therapeutics worth $564K as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 358,558 Fate Therapeutics shares in Q1 2026, an estimated $437K.
  • Fate Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1291 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Fate Therapeutics in Q1 2017 and has held it in 14 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Fate Therapeutics position peaked at $6.72M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.